EZH1

EZH1製品

  • All (2)
  • EZH1阻害剤 (2)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S7165 UNC1999 UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.
Cell Stem Cell, 2025, S1934-5909(25)00041-4
Cell Rep, 2025, 44(5):115673
bioRxiv, 2025, 2025.05.22.655558
UNC1999-S716501Z1520150908.gif
S7656 CPI-360 CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
Mol Ther Oncolytics, 2022, 27:14-25
Cancer Res, 2018, 78(20):5731-5740
S7165 UNC1999 UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM in cell-free assays, respectively, showing >1000-fold selectivity over a broad range of epigenetic and non-epigenetic targets. UNC1999 is a potent autophagy inducer. UNC1999 specifically suppresses H3K27me3/2 and induces a range of anti-leukemia effects including anti-proliferation, differentiation, and apoptosis.
Cell Stem Cell, 2025, S1934-5909(25)00041-4
Cell Rep, 2025, 44(5):115673
bioRxiv, 2025, 2025.05.22.655558
UNC1999-S716501Z1520150908.gif
S7656 CPI-360 CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
Mol Ther Oncolytics, 2022, 27:14-25
Cancer Res, 2018, 78(20):5731-5740